Almac's Clinical Supply Chain Management Service Responds to Growth in Demand for Biologics and Global Trials - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Almac's Clinical Supply Chain Management Service Responds to Growth in Demand for Biologics and Global Trials

Source: Company News Release

Almac’s best-in-class clinical Supply Chain Management (SCM) service combines consultancy and supportive technology that helps sponsor companies overcome technological, logistical and planning challenges increasingly experienced by biotech and pharma companies conducting global clinical trials.

As clinical studies become truly global, sponsor companies face challenges with shorter availability of complex investigational products, variable patient demands and the pressures on an increasingly stretched global supply chain. Coupled with the need for global provision of expensive comparators, sponsors are seeking oversight across all aspects of their clinical supply chain.

Almac have continued developing their unique SCM service that blends consultancy, supportive technology and end-to-end supply chain visibility. This gives sponsors more control over the complete supply chain, driving down costs, reducing timeframes and aligning clinical supply with patient demand globally.

The Almac solution of single system integration of forecasting, Material Resource Planning (MRP) and Interactive Response Technology (IRT) provides data in real-time. As a consequence, the dedicated SCM experts are able to assume responsibility to make key decisions, thereby ensuring reliable and efficient supply of clinical trial material to meet patient demand.

Almac’s latest service offering further enhances and supplements their core manufacturing, packaging and distribution services for investigational products and offers clients the best and most comprehensive clinical supply chain management solution available on the global marketplace.

Michelle Foust, Almac’s Director of Supply Chain Strategy stated “Almac has been providing clinical SCM for over 25 years and in response to the challenges experienced by our global client base, we have developed novel solutions for use across multiple study types. Indeed, we are confident that our consultancy-based offering optimizes clinical trial supply, thereby minimising waste and decreasing costs for our partners.”

Find out more about clinical Supply Chain Management – http://www.almac-scm.com

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here